公开(公告)号：US10603291B2

公开(公告)日：2020-03-31

申请号：US15712026

申请日：2017-09-21

申请人： Anji Pharma (US) LLC

发明人： Alain D. Baron ,  Mark S. Fineman ,  Nigel R. A. Beeley

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/155 ,  A61K45/06 ,  C07C279/26 ,  A61K31/4196 ,  A61K31/53 ,  A61K31/55 ,  C07D317/58 ,  C07D405/12 ,  C07D249/14 ,  C07D251/10 ,  C07D251/18 ,  C07D255/02 ,  C07D307/52 ,  A61K31/36 ,  A61K9/00

摘要： Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

公开(公告)号：US20210213111A1

公开(公告)日：2021-07-15

申请号：US15734461

申请日：2019-06-04

申请人： Anji Pharma (US) LLC

发明人： Charles D. Meyers ,  Brian K. Hubbard ,  Michael H. Serrano-Wu

IPC分类号： A61K38/48 ,  A61K31/7105 ,  C12N15/113

摘要： The present disclosure provides methods related to inhibiting or treating pancreatitis in a subject in need thereof, which include the use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor. The disclosed PCSK9 inhibitors and compositions including them can be used for treatment, inhibition, or prevention of pancreatitis in a subject. Treatment methods can include administering to the subject a therapeutically effective amount of a PCSK9 inhibitor.

公开(公告)号：US10668031B2

公开(公告)日：2020-06-02

申请号：US16037963

申请日：2018-07-17

申请人： Anji Pharma (US) LLC

发明人： Alain D. Baron ,  Mark S. Fineman ,  Nigel R. Beeley

IPC分类号： A61K31/155 ,  A61K31/53 ,  A61K45/06 ,  A61K9/20 ,  A61K9/24 ,  A61K9/28 ,  A61P3/10 ,  A61K9/00 ,  A61K9/16 ,  A61K31/137 ,  A61K31/341 ,  A61K31/343 ,  A61K31/357 ,  A61K31/36 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/485 ,  A61K31/55 ,  C07C279/26 ,  C07D207/06 ,  C07D207/34 ,  C07D211/14 ,  C07D249/14 ,  C07D251/10 ,  C07D251/18 ,  C07D255/02 ,  C07D307/52 ,  C07D307/66 ,  C07D317/58 ,  C07D401/04 ,  C07D405/12 ,  C07D409/12

摘要： Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

公开(公告)号：US20220151957A1

公开(公告)日：2022-05-19

申请号：US17375807

申请日：2021-07-14

申请人： Anji Pharma (US) LLC

发明人： Alain D. Baron ,  Mark S. Fineman ,  Nigel R.A. Beeley

IPC分类号： A61K31/155 ,  A61K9/20 ,  A61K9/48 ,  A61K9/28 ,  A61K45/06 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/40 ,  A61K31/53 ,  A61K31/4196 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/55 ,  A61P3/10 ,  A61P3/08 ,  A61K31/137 ,  A61K31/35 ,  A61K31/485

摘要： Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

公开(公告)号：US11065215B2

公开(公告)日：2021-07-20

申请号：US16223002

申请日：2018-12-17

申请人： Anji Pharma (US) LLC

发明人： Alain D. Baron ,  Mark S. Fineman ,  Nigel R. A. Beeley

IPC分类号： A61K31/155 ,  A61P3/10 ,  A61K9/20 ,  A61K9/48 ,  A61K9/28 ,  A61K45/06 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/40 ,  A61K31/53 ,  A61K31/4196 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/55 ,  A61K31/137 ,  A61K31/35 ,  A61K31/485

摘要： Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.